Headlines about Allergan (NYSE:AGN) have been trending positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 6,000 news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a media sentiment score of 2.17 on their scale. InfoTrie also gave media headlines about the company an news buzz score of 8 out of 10, indicating that recent news coverage is very likely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Allergan’s ranking:
A number of analysts have weighed in on AGN shares. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Wells Fargo & Co set a $232.00 target price on Allergan and gave the stock a “buy” rating in a report on Wednesday, August 22nd. Morgan Stanley set a $202.00 target price on Allergan and gave the stock an “overweight” rating in a report on Thursday, August 23rd. Deutsche Bank set a $210.00 price target on Allergan and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $180.00 price target on shares of Allergan in a research report on Friday, September 14th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $209.18.
Shares of AGN opened at $154.00 on Thursday. The stock has a market cap of $51.94 billion, a price-to-earnings ratio of 9.42, a P/E/G ratio of 1.19 and a beta of 1.29. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.78 and a current ratio of 0.92. Allergan has a fifty-two week low of $142.81 and a fifty-two week high of $197.00.
Allergan (NYSE:AGN) last posted its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.21. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same period in the prior year, the company posted $4.15 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. On average, analysts expect that Allergan will post 16.52 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.87%. The ex-dividend date of this dividend is Friday, November 9th. Allergan’s payout ratio is currently 17.61%.
In other news, CFO Matthew M. Walsh bought 1,000 shares of the stock in a transaction dated Friday, November 16th. The shares were acquired at an average cost of $157.00 per share, with a total value of $157,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Positive Media Coverage Very Likely to Affect Allergan (AGN) Stock Price” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/06/positive-media-coverage-very-likely-to-affect-allergan-agn-stock-price.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Recommended Story: Analyst Ratings
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.